---
title: Reduce gait freezing with cueing
nct_id: NCT06733077
phase: NA
status: RECRUITING
sponsor: University of Exeter
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06733077"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06733077"
last_fetched: "2026-05-10T14:07:59.597Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce gait freezing with cueing

**Goal (in five words):** Reduce gait freezing with cueing

**Official Title:** Development of Digital Diagnostics and Intervention Services for Parkinson's Disease

**Trial ID:** [NCT06733077](https://clinicaltrials.gov/study/NCT06733077)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** University of Exeter
- **Target Enrollment:** 80 participants
- **Start Date:** 2024-12-20
- **Completion Date:** 2026-04-01
- **Conditions:** Healthy Controls, Parkinson's Disease
- **Interventions:** gait with cueing wearable device and neuro-ocular performance
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to improve digital diagnosis and support for walking problems in Parkinson's, especially daily freezing of gait and the fast, shuffling steps called festination. The approach combines a wearable cueing device that delivers timed sensory prompts to the legs to help regularize stepping, with neuro-ocular tests that measure eye and visual-motor performance to detect instability and help tailor the intervention. Adults with Parkinson's who report daily freezing or festination, can walk for at least 5 minutes (with or without an aid), have MoCA scores above 21, and normal or corrected vision are eligible. Healthy adults can join as controls if they can walk at least 3 minutes and meet the same vision and cognition requirements, while people with implants like deep brain stimulators or pacemakers or skin issues on the calves are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion criteria Participants with Parkinson's \[Phase 1,2,3,4\]

* Diagnosis of idiopathic Parkinson's disease (UK Brain Bank Criteria) or other appropriate condition specific scale \[stroke, multiple sclerosis, arthritis or osteoporosis\]
* Able to self-report history of daily gait freezing and/or festination for people with PD or gait and/or transfers affected by condition
* Able to walk unsupported or using an aid for at least 5 minutes and satisfactory completion of the Canadian PARQ and if over 69 used to carrying out this level of exercise
* Adult (+18 years old)
* Normal or corrected-to-normal vision (Snellen Visual Acuity \> 12/18) or safe to mobilise with support
* Montreal Cognitive assessment score \>21 or ability to follow 2 stage commands

Healthy participants \[Phase 1,2,3\]

* With no long-term conditions affecting movement
* Able to walk unsupported or using an aid for at least 3 minutes and satisfactory completion of the Canadian PARQ and if over 69 used to carrying out this level of exercise
* Adult (+18 years old)
* Normal or corrected-to-normal vision (Snellen Visual Acuity \> 12/18) or safe to mobilise with support
* Montreal Cognitive assessment score \>21 or ability to follow 2 stage commands

Exclusion criteria Participants with Parkinson's

* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.
* Cognitive impairment affecting ability to safely participate and follow instructions
* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)
* Any skin conditions or broken skin in the calf and behind knee area
* Deep brain stimulation or pacemaker implants or other implant that may interfere with the measurement system
* Medications likely to affect eye sight or use of virtual reality sytstem

Healthy participants

* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.
* Cognitive impairment affecting ability to safely participate and follow instructions
* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)
* Any skin conditions or broken skin in the calf and behind knee area
* Deep brain stimulation or pacemaker implants or other implants that may interfere with the measurement system
```

## Locations (1)

- University of Exeter, Exeter, United Kingdom _(50.7236, -3.5275)_
  - Helen Dawes — (CONTACT) — 00441392402969 — h.dawes@exeter.ac.uk

## Central Contacts

- Pavlos Evangelidis, PhD — (CONTACT) — 00447866138722 — p.evangelidis@exeter.ac.uk
- Helen Dawes, PhD — (CONTACT) — 01392 40 2969 — H.Dawes@exeter.ac.uk

---

*Canonical: https://parkinsonspathways.com/trial/NCT06733077*  
*HTML version: https://parkinsonspathways.com/trial/NCT06733077*  
*Source data: https://clinicaltrials.gov/study/NCT06733077*